• Loading stock data…

day trading

Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It

On Friday May 24th, 2019 Novartis (NYSE: NVS) gained FDA approval of its gene therapy product " Zolgensma® " for spinal muscular atrophy (SMA), originally purchased from AveXis in 2018 for $8.7 … [Read more...] about Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It

A High-Risk, High-Reward Biotech Stock Targeting NASH Cirrhosis

In this next article in our series on investing in NASH I want to jump to the other end of the spectrum. In "Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years" I painted a … [Read more...] about A High-Risk, High-Reward Biotech Stock Targeting NASH Cirrhosis